Shanghai Henlius Biotech Partners with Avanc Pharma for Fovinaciclib Citrate Capsules
Shanghai Henlius Biotech Inc. has partnered with Avanc Pharma to commercialize fovinaciclib citrate capsules in China. Under the agreement, Avanc Pharma grants Henlius an exclusive license for distribution in designated areas. This collaboration follows a prior memorandum and outlines supply and commercialization services, with Henlius managing distribution where Avanc Pharma is authorized to sell. The original content was published by Shanghai Henlius Biotech via the Hong Kong Stock Exchange's Issuer Information Service.
Shanghai Henlius Biotech Inc. has entered into collaboration agreements with Avanc Pharma for the commercialisation of fovinaciclib citrate capsules. Under the terms of the agreements signed on December 3, 2025, Avanc Pharma will grant Henlius an exclusive license to commercialise the licensed product in designated areas and channels within China. The partnership follows a prior memorandum of cooperation and sets out arrangements for supply and commercialisation services, with Henlius handling distribution in regions where Avanc Pharma is permitted to sell the product under local policies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251203-11942832), on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
